Precision BioSciences Q3 revenue $7.4M, net loss $23.9M; discontinues PBCAR269A program

PRECISION BIOSCIENCES INC

2022-Q3 EPS reported -$1.04 revenue$14,500,000

Net loss of $23.9M ($0.22 loss per share) vs $11.3M loss ($0.19) in Q3 2021.
Revenue $7.4M, down 69% from $24M YoY; decrease primarily from absence of iECURE revenue.
Cash $212.1M; expects runway to fund operations through end of 2024.
Discontinued BCMA CAR T program PBCAR269A due to competitive landscape; no further clinical spending planned.
Planned clinical update for azer-cel (PBCAR0191) and PBCAR19B in late Q4 2022 or early Q1 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-22-022894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.